Catalyst
Slingshot members are tracking this event:
Pulmatrix Initiates European Pilot Bioequivalence Study of PUR0200 for COPD; topline results are expected to be reported in the second quarter of 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PULM | Community voting in process | |||||
Additional Information
The trial is a seven-period crossover study in 42 healthy volunteers. The trial will evaluate pharmacokinetics (PK) and safety and tolerability of five unique PUR0200 formulations compared to two dosing periods of a marketed reference product. The five unique PUR0200 formulations vary in aerosol properties and strength. PUR0200 is being developed under the PK bioequivalence regulatory pathway for orally inhaled drugs in Europe.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 19, 2016
Occurred Source:
http://ir.pulmatrix.com/2016-07-19-Pulmatrix-and-Mylan-Report-Positive-Pharmacokinetic-Bioavailability-Data-in-Pilot-Study-of-PUR0200-in-Patients-with-Chronic-Obstructive-Pulmonary-Disease-COPD
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Bioequivalence Study, Pur0200, Copd
